Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has announced a non-brokered private placement of 6,764,069 units priced at C$0.7392 per unit, for gross proceeds of approximately C$5 million. Each unit consists of one common share and one warrant exercisable at C$0.90 per share for a period of three years. The financing is expected to close on or about July 10, 2026, subject to regulatory approvals, including approval from Cboe Canada.
The company stated that proceeds from the private placement will be used to advance its ONC010 program through manufacturing and preclinical testing activities, support the development of its SynoGraph(TM) platform, and provide working capital for general corporate purposes. The offering is being conducted under Canada’s Listed Issuer Financing Exemption, and securities issued under the financing will not be subject to a hold period under applicable Canadian securities laws.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumours. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF.
This capital raise is significant for Onco-Innovations as it provides the necessary funding to progress ONC010, a key asset in its pipeline, through critical development stages. The ONC010 program targets solid tumours, a major area of unmet medical need, and the SynoGraph platform represents a novel approach to cancer treatment. The successful completion of this private placement allows the company to move forward with manufacturing and preclinical testing, which are essential steps toward clinical trials and eventual commercialization.
For investors, this announcement signals that Onco-Innovations has secured funding to execute its development plans, reducing near-term dilution risk and providing a clearer path to value-creating milestones. The use of the Listed Issuer Financing Exemption also streamlines the process and removes the typical hold period on securities, which may enhance liquidity for investors. The full press release can be viewed at https://www.nnw.fm/QatCe.
Overall, the private placement positions Onco-Innovations to advance its oncology pipeline and platform technology, potentially addressing significant challenges in cancer treatment. The funding is a critical step toward bringing innovative therapies to patients and creating shareholder value.
